Navigation Links
Verenium Reports Financial Results for the Third Quarter 2010

CAMBRIDGE, Mass., Nov. 9, 2010 /PRNewswire-FirstCall/ -- Verenium Corporation (Nasdaq: VRNM), a pioneer in the development and commercialization of high-performance industrial enzyme solutions, today reported a summary of recent Company highlights and financial results for the third quarter of 2010.

"I am pleased with the significant progress made across the business over the last quarter; we continue to see solid progress growing and diversifying our product sales and improved performance at the gross margin level," said Carlos A. Riva, President and Chief Executive Officer of Verenium. "Further, we remain committed to using our financial resources to accelerate the development of our current products and our pipeline."

Company HighlightsDuring 2010 Verenium has made significant progress on both the operational and financial fronts.  Most recent accomplishments include:

Operational/Industry Performance:

Animal Health and Nutrition

  • Achieved a 34% increase in 2010 year-to-date profit share from Phyzyme sales over the same period in 2009 due to strong demand for Phyzyme phytase.

  • Grain Processing

  • Launched Deltazym® GA L-E5 for fuel ethanol production, which together with Fuelzyme, allows us to satisfy the complete enzyme requirements of corn ethanol producers; and
  • Grew 2010 year-to-date revenues from the Company's grain processing enzymes, including Fuelzyme, Deltazym, Veretase and Xylathin, by 37% over the same period in 2009; grain processing has grown to represent more than 25% of 2010 year-to-date product revenues.

  • Oilseed Processing

  • Received regulatory approval for sale of Purifine® PLC in China, completing the product's approval for sale in all the major oilseed processing areas of the world, which include Argentina, Brazil, the United States and China;
  • Renewed and extended the Company's successful joint marketing agreement with Alfa Laval for Purifine® PLC for five years; and
  • Licensed a new lipase enzyme for use in the production of edible oil products to Bunge Oils, Inc.

  • Manufacturing

  • Hired Kevin Bracken as Vice President of Manufacturing to lead the optimization and expansion of manufacturing capabilities; and
  • Acquired control of additional fermentation capacity at Fermic, the Company's contract manufacturing facility in Mexico City.

  • Corporate/Financial:

  • Completed the sale of the Company's cellulosic biofuels business to BP, including facilities in Jennings, LA and San Diego, CA for net cash proceeds of $95.4 million;
  • Repurchased $21 million in principal amount of 8% and 5.5% Notes, eliminating all outstanding 8% Notes;
  • Appointed Alexander Fitzpatrick as Senior Vice President and General Counsel, further building out the senior management team;
  • Ended the quarter with unrestricted cash and cash equivalents totaling $89 million;
  • Increased total product revenue by 11% and 16% for the three and nine months ended September 30, 2010 respectively, when compared to the same periods in 2009;
  • Improved revenue mix from increasing sales of Company's newer enzymes including Fuelzyme, Xylathin, Veretase and Purifine; and
  • Increased product gross margin dollars by 17% and 20% for the three and nine months ended September 30, 2010 as compared to the same periods in 2009.

  • "The third quarter was an important quarter for Verenium in terms of demonstrating the growth potential of our enzyme products in all our industry areas," said James E. Levine, Executive Vice President and Chief Financial Officer.  "With the close of the BP transaction, we now have the financial flexibility to invest in the company and grow our enzymes business."

    Financial ResultsIn the commentary below, the historical results of the Company's cellulosic biofuels business for current and prior periods have been reclassified into discontinued operations as a result of the sale of the cellulosic biofuels business on September 2, 2010 to BP.


    Revenues for the periods ended September 30, 2010 and 2009 were as follows (in thousands): Three Months Ended 
    September 30,Nine Months Ended 
    September 30,2010200920102009Revenues:Animal Health and Nutrition

    23,846Grain Processing

    3,3642,5249,6057,016All other products

    1,1735832,9431,232Total product


    3399031,3913,369Total revenues

    35,463Total revenues for the nine months ended September 30, 2010 increased 8% to $38.5 million from $35.5 million for the same period in the prior year, with product revenues representing more than 90 percent of total revenues in both periods. Product revenues for the nine months ended September 30, 2010 increased 16% to $37.1 million from $32.1 million for same period in the prior year, primarily due to an increase in Phyzyme profit share from Danisco, as well as an increase in revenues from grain processing enzymes, Fuelzyme, Veretase and Xylathin, which continued to gain acceptance in the grain ethanol markets, and Purifine enzyme for the soybean oil processing market. Product revenue from non-Phyzyme products as a percentage of total product revenue increased to 34% for the nine months ended September 30, 2010 compared to 26% for the same period in the prior year.

    Product Gross Profit

    Product gross profit for the nine months ended September 30, 2010 increased to $13.9 million from $11.6 million for the same period in the prior year, primarily due to improved fixed cost leverage on higher revenue, partially offset by the impact of manufacturing constraints compared to the prior year, resulting from the challenges of satisfying increased demand for our products and expanded product mix.

    Operating Expenses (excluding cost of product revenue)

    Excluding cost of product revenues, total operating expenses related to continuing operations decreased $4.3 million to $25.1 million (including share-based compensation of $0.8 million) for the nine months ended September 30, 2010 from $29.4 million (including share-based compensation of $3.9 million) for the same period in the prior year.  Excluding the impact of share-based compensation, total operating expenses decreased $1.2 million primarily due to $2.1 million of debt issuance costs during the third quarter of 2009 related to our 2007 Notes exchange and 2008 Notes amendment, partially offset by $1.4 million in bonus payments expensed during the third quarter of 2010.

    Net Loss from Continuing Operations

    Net loss from continuing operations for the nine months ended September 30, 2010 was $11.9 million compared to a net loss of $5.7 million for the same period in 2009, on a GAAP accounting basis. Adjusted for the non-cash impact of the tax benefit from income from discontinued operations, gains on debt extinguishment and amendments, and gains and losses for fair value remeasurements related to the 8% and 9% convertible notes, the Company's non-GAAP pro-forma net loss from continuing operations for the nine months ended September 30, 2010 was $16 million compared to $23.4 million for the same period in the prior year. The Company believes that excluding the impact of these items provides a more consistent measure of operating results.  

    Net Income (Loss) from Discontinued Operations

    For the nine months ended September 30, 2010, net income from discontinued operations was $9.8 million and included a $46.9 million gain on sale of the cellulosic biofuels business (net of tax provision of $9.6 million) compared to a net loss from discontinued operations of $38.7 million for the same period in 2009.

    About VereniumVerenium Corporation is a pioneer in the development and commercialization of high-performance enzymes for use in industrial processes.  Verenium currently sells enzymes developed using its R&D capabilities to industrial customers globally for use in markets including grain and oilseed processing, biofuels, animal health and nutrition and other specialty industrial processes. Verenium has built a world-class R&D organization renowned for its capabilities in the rapid screening, identification, evolution and bioengineering of novel enzymes that act as catalysts for biochemical reactions. The company harnesses the power of nature and uses its unique, patented technology to create products that transform industries by maximizing efficiency while improving environmental performance. For more information on Verenium, visit

    Forward-Looking StatementsStatements in this press release that are not strictly historical are "forward-looking" and involve a high degree of risk and uncertainty.  These include, but are not limited to, statements related to Verenium's lines of business, operations, capabilities, commercialization activities, corporate partnerships, target markets and future financial performance, results and objectives, all of which are prospective.  Such statements are only predictions, and actual events or results may differ materially from those projected in such forward-looking statements.  Factors that could cause or contribute to the differences include, but are not limited to, risks associated with Verenium's strategic focus, risks associated with Verenium's technologies, risks associated with Verenium's ability to obtain additional capital to support its planned operations and financial obligations, risks associated with Verenium's dependence on patents and proprietary rights, risks associated with Verenium's protection and enforcement of its patents and proprietary rights, the commercial prospects of the industries in which Verenium operates and sells products, Verenium's dependence on manufacturing and/or license agreements, and its ability to achieve milestones under existing and future collaboration agreements, the ability of Verenium and its partners to commercialize its technologies and products (including by obtaining any required regulatory approvals) using Verenium's technologies and timing for launching any commercial products and projects, the ability of Verenium and its collaborators to market and sell any products that it or they commercialize, the development or availability of competitive products or technologies, the future ability of Verenium to enter into and/or maintain collaboration and joint venture agreements and licenses, and risks and other uncertainties more fully described in Verenium's filings with the Securities and Exchange Commission, including, but not limited to, Verenium's annual report on Form 10-K for the year ended December 31, 2009 and any updates contained in its subsequently filed quarterly reports on Form 10-Q.  These forward-looking statements speak only as of the date hereof, and Verenium expressly disclaims any intent or obligation to update these forward-looking statements.

    Contacts:Kelly Lindenboom

    Vice President, Corporate Communications


    kelly.lindenboom@verenium.comSarah Carmody

    Manager, Corporate Communications


    sarah.carmody@verenium.comVerenium CorporationConsolidated Statements of Operations(unaudited, in thousands, except per share amounts)Three Months Ended
    September 30, Nine Months Ended
    September 30, 2010200920102009Revenues:   Product

    32,094   Collaborative  

    3399031,3913,369Total revenue

    12,57211,92938,47635,463Operating expenses:   Cost of product revenue

    7,8337,27823,17920,483Product Gross Profit

    4,4003,74813,90611,611Product Gross Margin

    36%34%37%36%   Research and development

    1,4481,6504,1244,808   Selling, general and administrative

    7,8389,02421,01024,594Total operating expenses

    17,11917,95248,31349,885Operating loss from continuing operations

    (4,547)(6,023)(9,837)(14,422)Other Income and Expense:   Interest and other expense, net

    (2,072)(2,567)(6,179)(8,980)   Gain (loss) on debt extinguishment

    (3,384)2,511(2,786)8,629   Gain on amendment of 2008 Notes

    --3,977--3,977   Gain (loss) on net change in fair value of derivativeassets and liabilities

    (299)1,712(1,017)5,078Total other income (expense), net

    (5,755)5,633(9,982)8,704Loss from continuing operations before income taxes

    (10,302)(390)(19,819)(5,718)Income tax benefit

    7,928--7,928--Net loss from continuing operations

    (2,374)(390)(11,891)(5,718)Discontinued Operations:   Net income (loss) from discontinued operations,net of income taxes

    31,980(10,607)9,841(38,715)Less: Loss attributed to noncontrolling interests in   consolidated entities – discontinued operations

    10,1088,70525,28325,500Net income (loss) attributed to Verenium

    (18,933)Basic and diluted net income (loss) per share:Continuing Operations

    (0.77)Discontinued Operations

    (5.19)Net income (loss) attributed to Verenium

    (2.54)Shares used in computing basic and diluted net income  (loss) per share

    12,3719,01412,2317,466Verenium CorporationCondensed Consolidated Balance Sheet Data(unaudited, in thousands)September 30,December 31,20102009Cash and cash equivalents

    24,844Accounts receivable, net

    8,5246,558Inventory, net

    4,4592,586Other current assets  

    2,9702,500Restricted cash

    5,00010,400Property and equipment, net  

    2,1614,169Other noncurrent assets  

    1,0722,020Assets of discontinued operations

    --114,845Total assets  

    7,922Current liabilities, excluding deferred revenue and liabilities of discontinued operations

    ,523Deferred revenue  

    1,1131,365Convertible notes, at carrying value

    88,969105,756Other long term liabilities  

    9011,264Liabilities of discontinued operations  

    3,76418,812Stockholders' equity  

    5,62930,202Total liabilities, noncontrolling interests and stockholders' equity

    7,922Verenium CorporationUnaudited Supplemental and Non-GAAP Pro Forma Financial Information(in thousands, except per share amounts)The following unaudited supplemental and non-GAAP pro forma financial information is derived from the Company's condensed consolidated financial statements for the three- and nine-month periods ended September 30, 2010 and 2009, as reported under GAAP. The Company believes that such supplemental and non-GAAP financial information is helpful to understand the results of operations of the business.Non-GAAP Pro Forma Net Loss From Continuing OperationsThree Months Ended
    September 30,Nine Months Ended
    September 30,2010200920102009 Net loss from continuing operations

    (5,718)   Adjustments:  Income tax benefit

    (7,928)--(7,928)--Gain on amendment of 2008 Notes

    --(3,977)--(3,977)   (Gain) loss on debt extinguishment

    3,384(2,511)2,786(8,629)   (Gain) loss on net change in fair value of derivative assets and liabilities 299   (1,712)1,017(5,078)   Non-GAAP pro forma net loss from continuing operations  

    (23,402)Non-GAAP pro forma net loss from continuing operations per share  


    SOURCE Verenium Corporation
    Copyright©2010 PR Newswire.
    All rights reserved

    Related biology technology :

    1. Verenium to Present at Jefferies 10th Global Clean Technology Conference
    2. Verenium and Alfa Laval Announce Extension of Purifine® PLC Enzyme Agreement
    3. Verenium Announces Regulatory Approval for Purifine® PLC in China
    4. Verenium Launches DELTAZYM® GA L-E5 Enzyme for Fuel Ethanol Production
    5. Verenium Appoints Kevin Bracken Vice President of Manufacturing
    6. Verenium Announces Proposed Public Offering of Common Stock
    7. Verenium 1:12 Reverse Stock Split Takes Effect
    8. Verenium Announces Reverse Stock Split to Take Effect September 9
    9. BP and Verenium Announce Vercipia Biofuels to Advance the Commercialization of Cellulosic Ethanol
    10. Verenium Completes Amendment to 8% Senior Convertible Notes
    11. Verenium Announces Organizational Changes
    Post Your Comments:
    (Date:11/24/2015)... ... November 24, 2015 , ... Copper is an essential ... bound to proteins, copper is also toxic to cells. With a $1.3 million ... (WPI) will conduct a systematic study of copper in the bacteria Pseudomonas aeruginosa ...
    (Date:11/24/2015)... Inc., a worldwide provider of clinical research services headquartered in ... has set a new quarterly earnings record in Q3 of 2015.  ... Q3 of 2014 to Q3 of 2015.   ... the establishment of an Asia-Pacific office to ... and Mexico , with the establishment ...
    (Date:11/24/2015)... ... November 24, 2015 , ... The Academy of Model ... Group (SIG), MultiGP, also known as Multirotor Grand Prix, to represent the First–Person View ... years. Many AMA members have embraced this type of racing and several new model ...
    (Date:11/24/2015)... Ltd. (OTCQB: TIKRF) today announced that its Annual General Meeting of Shareholders ... Israel time, at the law offices of Goldfarb Seligman ... Floor, Tel Aviv, Israel . ... to the Board of Directors; , election of Liat ... an amendment to certain terms of options granted to our Chief Executive ...
    Breaking Biology Technology:
    (Date:10/29/2015)... Oct. 29, 2015  Rubicon Genomics, Inc., today ... distribution of its DNA library preparation products, including ... new ThruPLEX Plasma-seq kit. ThruPLEX Plasma-seq has been ... of NGS libraries for liquid biopsies--the analysis of ... prognostic applications in cancer and other conditions. Eurofins ...
    (Date:10/27/2015)... 27, 2015 Munich, Germany ... Mapping technology (ASGM) automatically maps data from mobile eye ... , so that they can be quantitatively analyzed ... Munich, Germany , October 28-29, 2015. SMI,s ... from mobile eye tracking videos created with SMI,s ...
    (Date:10/23/2015)... DUBLIN , Oct. 23, 2015 Research ... of the "Global Voice Recognition Biometrics Market 2015-2019" ... --> --> The global voice recognition ... during 2014-2019. --> ... 2015-2019, has been prepared based on an in-depth market ...
    Breaking Biology News(10 mins):